Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts
نویسندگان
چکیده
منابع مشابه
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
The role of androgen receptor (AR) mutations in androgen-independent prostate cancer (PCa) was determined by examining AR transcripts and genes from a large series of bone marrow metastases. Mutations were found in 5 of 16 patients who received combined androgen blockade with the AR antagonist flutamide, and these mutant ARs were strongly stimulated by flutamide. In contrast, the single mutant ...
متن کاملPhase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
4654 Background: Docetaxel is a microtubule stabilizing agent with documented clinical activity in patients with advanced prostate cancer. Bortezomib (Velcade, formerly PS-341) is a small molecule that is a potent and reversible proteasome inhibitor with evidence of anti-tumor activity in prostate cancer models. Following completion of the phase I portion of this study during which MTD was not ...
متن کاملPhase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Purpose: To determine the dose-limiting toxicities and maximum tolerated dose, and evaluate the antitumor activity of bortezomib/docetaxel combination therapy in androgen-independent prostate cancer. Experimental Design: Two bortezomib doses (1.3 and 1.6 mg/m/dose) in combination with four docetaxel doses (25-40 mg/m/dose) were evaluated. Both drugs were administered weekly for 2 out of 3 weeks...
متن کاملTranscription factor Stat5 synergizes with androgen receptor in prostate cancer cells.
The molecular mechanisms underlying progression of prostate cancer to the hormone-independent state are poorly understood. Signal transducer and activator of transcription 5a and 5b (Stat5a/b) is critical for the viability of human prostate cancer cells. We have previously shown that Stat5a/b is constitutively active in high-grade human prostate cancer, but not in normal prostate epithelium. Fu...
متن کاملAndrogen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
Human prostate cancer (PC) overexpresses the gastrin-releasing peptide receptor (GRPR). Radiolabeled GRPR-targeting analogs of bombesin (BN) have successfully been introduced as potential tracers for visualization and treatment of GRPR-overexpressing tumors. A previous study showed GRPR-mediated binding of radiolabeled BN analogs in androgen-dependent but not in androgen-independent xenografts ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine-Related Cancer
سال: 2014
ISSN: 1351-0088,1479-6821
DOI: 10.1530/erc-14-0088